Merck & Co., Inc. $MRK Shares Acquired by Parallel Advisors LLC

Parallel Advisors LLC lifted its holdings in Merck & Co., Inc. (NYSE:MRK) by 7.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 56,169 shares of the company’s stock after acquiring an additional 3,968 shares during the quarter. Parallel Advisors LLC’s holdings in Merck & Co., Inc. were worth $6,757,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Kingdom Financial Group LLC. purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter worth about $26,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. during the fourth quarter worth about $26,000. IFC & Insurance Marketing Inc. acquired a new stake in Merck & Co., Inc. during the fourth quarter worth about $31,000. Finally, High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $128.33 on Thursday. The stock’s fifty day moving average is $123.61 and its two-hundred day moving average is $118.91. The firm has a market capitalization of $316.95 billion, a P/E ratio of 102.66, a price-to-earnings-growth ratio of 5.13 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.05.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same period in the prior year, the business earned $2.13 EPS. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 2.72 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on MRK. UBS Group lifted their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Scotiabank raised their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a report on Tuesday, June 30th. Wells Fargo & Company upped their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th. Finally, Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Thirteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $134.56.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate, while its adjusted loss of $0.13 per share was narrower than the expected $0.26 loss. Revenue grew 5.1% year over year. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda remained the primary growth driver, generating $8.37 billion in quarterly sales, while the injectable formulation substantially exceeded Wall Street expectations. Newer products and pipeline programs also supported the company’s performance. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Positive Sentiment: Merck raised its 2026 revenue outlook to $66.3 billion-$67.3 billion, reflecting confidence in Keytruda, newer launches and pipeline progress. Guggenheim also raised its price target to $146 and maintained a Buy rating. MRK Q2 Earnings & Sales Beat Estimates, ’26 Sales View Raised
• Positive Sentiment: Health Canada approved Keytruda combined with enfortumab vedotin for certain cisplatin-ineligible patients with muscle-invasive bladder cancer, expanding the drug’s commercial reach. Health Canada approves Keytruda treatment
• Neutral Sentiment: Merck is accelerating acquisitions and partnerships in hematology, infectious diseases, vaccines, cardiopulmonary medicine and obesity to diversify ahead of Keytruda’s expected U.S. patent-exclusivity loss in 2028. The strategy offers long-term upside but increases execution and spending risks. Merck is racing beyond Keytruda
• Negative Sentiment: Merck lowered its 2026 EPS guidance to $2.66-$2.76, well below the $3.42 consensus, primarily because of acquisition-related charges tied to Terns Pharmaceuticals and other deals. Merck hikes revenue outlook but cuts profit guidance
• Negative Sentiment: Investors remain concerned that Keytruda’s 2028 patent cliff could create a significant revenue gap unless newer products, acquisitions and clinical programs deliver sufficient replacement growth. Merck also reported a mixed development update for anti-TL1A drug tulisokibart, which was discontinued in one rare lung-disease indication. MSD posts a victory and defeat for anti-TL1A

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.